topotecan has been researched along with Astrocytoma, Grade IV in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (11.90) | 18.2507 |
| 2000's | 27 (64.29) | 29.6817 |
| 2010's | 7 (16.67) | 24.3611 |
| 2020's | 3 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, H; Elkamhawy, A; Heo, JC; Kim, HY; Kim, KH; Lee, CO; Nam, DH; Pae, AN; Park, WK; Roh, EJ; Seol, HJ; Viswanath, AN; Yang, H | 1 |
| Agar, NYR; Al-Dalahmah, O; Argenziano, MG; Banu, MA; Behl, M; Boyett, DM; Bruce, JN; Canoll, P; Catania, V; D'Amico, RS; Furnari, JL; Gill, BJA; Good, L; Grinband, J; Higgins, DMO; Humala, N; Iwamoto, FM; Jambawalikar, S; Lassman, AB; Lignelli, A; Mahajan, A; Marie, T; Mintz, A; Neira, JA; Pereira, B; Petridis, P; Regan, MS; Save, AV; Sims, PA; Spinazzi, EF; Stopka, SA; Sudhakar, TD; Upadhyayula, PS; Welch, MR; Wu, PB; Zacharoulis, S; Zhao, W | 1 |
| Rubinstein, A; Sharon Gabbay, R | 1 |
| Eynali, S; Eyvazzadeh, N; Kamalabadi, MA; Koosha, F | 1 |
| Baumgarten, P; Bernstock, JD; Gessler, FA; Hallenbeck, JM; Johnson, KR; Kögel, D; Lee, YJ; Maric, D; Peruzzotti-Jametti, L; Pluchino, S; Yang, W; Ye, D | 1 |
| Eynali, S; Eyvazzadeh, N; Koosha, F; Mazaheri, Z; Mousavi, M; Neshasteh-Riz, A; Takavar, A | 1 |
| Allen, GI; Liu, Z; Raman, AT; Yi, H; Zhang, H | 1 |
| Carlomagno, C; Della Vittoria Scarpati, G; Ferrone, S; Fusciello, C; Leonardi, A; Pacelli, R; Pepe, S; Pepin, D; Poudel, R; Sabbatino, F; Somma, D | 1 |
| DeAngulo, G; Heimberger, AB; Hussain, SF; Jordan, J; Koshkina, N; Sun, W; Vasquez, H; Wei, J; Weinberg, J; Wolff, J | 1 |
| Bay, JO; Ben Hassel, M; Carsin, B; Fabbro, M; Frappaz, D; Gédouin, D; Guégan, Y; Hamlat, A; Lesimple, T; Linassier, C; Piot, G; Riffaud, L; Saïkali, S | 1 |
| Bankiewicz, KS; Bringas, JR; Dugich-Djordjevic, M; Eastman, S; Grahn, AY; Hadaczek, P; Johnson, GA; Luz, M | 1 |
| Birkmann, J; Ganslandt, O; Gerber, KD; Grabenbauer, GG; Klautke, G; Meyer, M; Richter, A | 1 |
| Assanah, MC; Bruce, JN; Canoll, P; Gil, OD; Kangarlu, A; Linskey, K; Lopez, KA; Tannenbaum, AM; Yun, J | 1 |
| Drummond, DC; James, CD; Kirpotin, DB; Michaud, K; Noble, CO; Ozawa, T; Park, JW; Prados, MD; Serwer, LP | 1 |
| Glomme, S; Hertig, J; Hess, CF; Pradier, O; Rave-Fränk, M; Schmidberger, H; Virsik-Köpp, P; Weiss, E | 1 |
| Anders, K; Feldmann, HJ; Fietkau, RJ; Grabenbauer, GG; Klautke, G; Krauseneck, P; Sauer, R; Staab, HJ; Weiser, S | 1 |
| Carsin, B; Gédouin, D; Guégan, Y; Hamlat, A; Hassel, MB; Lesimple, T; Malhaire, JP; Riffaud, L; Seigneuret, E; Simon, H | 1 |
| Bonomi, CA; Borgel, SD; Braunschweig, T; Carter, JP; Hewitt, SM; Hollingshead, M; Melillo, G; Rapisarda, A; Shoemaker, RH; Uranchimeg, B; Zalek, J | 1 |
| Cromwell, LD; Fadul, CE; Kingman, LS; McDonnell, CE; Meyer, LP; Pipas, JM; Rhodes, CH; Rigas, JR | 1 |
| Altscher, R; Brandtner, M; Chiricuta, IC; Engenhart-Cabillic, R; Gross, MW; Haeusser-Mischlich, H; Siegmann, AD | 1 |
| Kehlbach, R; Ohneseit, PA; Prager, D; Rodemann, HP | 1 |
| Hansen, LT; Kristjansen, PE; Lund, EL | 1 |
| Benecke, R; Bombor, I; Fietkau, R; Klautke, G; Piek, J; Schütze, M | 1 |
| Kondo, S; Kondo, Y | 1 |
| Bankiewicz, KS; Drummond, DC; Kawaguchi, T; Krauze, MT; Noble, CO; Park, JW; Yamashita, Y | 1 |
| Chianese, M; Cimmino, G; Laus, G; Penitente, R; Pepe, S; Prece, D; Quesada, P | 1 |
| Fels, C; Hau, P; Janssen, G; Liebeskind, AK; Peters, O; Sauerbrey, A; Suttorp, M; Wagner, S; Wolff, JE | 1 |
| Asadpour, B; Eble, MJ; Gagel, B; Pinkawa, M; Piroth, MD; Stanzel, S | 1 |
| Mazonakis, M; Petinelli, E; Stratakis, J; Varveris, H | 1 |
| Grosse-Hovest, L; Herrmann, T; Jung, G; Krammer, PH; Otz, T; Rammensee, HG | 1 |
| Feun, L; Savaraj, N | 1 |
| Danks, MK; Garrett, KE; Marion, RC; Whipple, DO | 1 |
| Capranico, G; Caserini, C; Colombo, A; Marchesini, R; Perego, P; Supino, R; Tronconi, M; Zunino, F | 1 |
| Adamson, PC; Allen, JC; Balis, FM; Berg, SL; Blaney, SM; Heideman, RL; Horowitz, ME; Jakacki, RI; Lange, BJ; Packer, RJ; Phillips, PC; Poplack, DG; Reaman, GH; Sallan, SE | 1 |
| Cairncross, G; Eisenhauer, E; Forsyth, P; Macdonald, D; Sawka, C; Stewart, D; Wainman, N | 1 |
| Buchfelder, M; Fahlbusch, R; Grabenbauer, GG; Sauer, R; Schrell, U; Staab, HJ | 1 |
| Dichgans, J; Esser, P; Meyermann, R; Rieger, J; Rieger, L; Streffer, J; Weller, M; Winter, S | 1 |
| Prados, MD | 1 |
| Coughlin, C; Curran, WJ; Fisher, BJ; Macdonald, DR; Scott, C | 1 |
| Chastagner, P; Kozin, SV; Taghian, A | 1 |
| Altscher, R; Brandtner, M; Engenhart-Cabillic, R; Gross, MW; Häusser-Mischlich, H; Kiricuta, IC; Siegmann, AD | 1 |
| Fisher, B; Johnson, DW; Macdonald, D; Roa, W; Won, M | 1 |
2 review(s) available for topotecan and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Topoisomerase I inhibitors for the treatment of brain tumors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local; Survival Analysis; Topoisomerase I Inhibitors; Topotecan | 2008 |
Future directions in the treatment of malignant gliomas with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Genetic Therapy; Glioblastoma; Humans; Temozolomide; Topotecan | 2000 |
16 trial(s) available for topotecan and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial.
Topics: Convection; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Topotecan | 2022 |
Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Drug Administration Schedule; Epilepsy; Female; Follow-Up Studies; Glioblastoma; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Patient Selection; Radiotherapy Dosage; Survival Analysis; Time Factors; Topotecan; Young Adult | 2009 |
Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Radiotherapy Dosage; Topotecan; Young Adult | 2009 |
Prolonged infusional topotecan and accelerated hyperfractionated 3d-conformal radiation in patients with newly diagnosed glioblastoma--a phase I study.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Combined Modality Therapy; Glioblastoma; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neutropenia; Radiotherapy, Conformal; Sepsis; Sinusitis; Thrombocytopenia; Topotecan | 2002 |
Phase I study of topotecan in combination with concurrent radiotherapy in adults with glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Female; Glioblastoma; Humans; Infusion Pumps; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Topotecan | 2003 |
A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Filgrastim; Glioblastoma; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Recombinant Proteins; Thrombocytopenia; Topotecan; Treatment Outcome | 2005 |
Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival; Feasibility Studies; Female; Glioblastoma; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Quality of Life; Survival Rate; Topotecan | 2005 |
Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; Middle Aged; Survival Analysis; Topotecan; Treatment Outcome | 2006 |
Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Child; Child, Preschool; Choroid Plexus Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Eruptions; Glioblastoma; Hematologic Diseases; Humans; Neoplasm Recurrence, Local; Polyethylene Glycols; Recurrence; Retrospective Studies; Stomatitis; Topotecan; Treatment Outcome | 2008 |
Phase I study of weekly topotecan combined to concurrent external cranial irradiation in adults with glioblastoma multiforme of the brain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Topotecan; Treatment Outcome | 2008 |
Phase II evaluation of topotecan for pediatric central nervous system tumors.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Brain Stem; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Infant; Infusions, Intravenous; Male; Topotecan | 1996 |
Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioblastoma; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Topotecan; Treatment Outcome | 1996 |
Topotecan as a 21-day continuous infusion with accelerated 3D-conformal radiation therapy for patients with glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Glioblastoma; Humans; Infusions, Intravenous; Middle Aged; Radiotherapy, Conformal; Topotecan | 1999 |
Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507.
Topics: Adolescent; Adult; Antineoplastic Agents; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Neutropenia; Survival Analysis; Topotecan | 2001 |
Acute toxicity and changes in quality of life during a combined radio-chemotherapy of glioblastomas with topotecan (Hycamtin).
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Data Interpretation, Statistical; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Prospective Studies; Quality of Life; Radiotherapy; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Analysis; Time Factors; Topoisomerase I Inhibitors; Topotecan | 2001 |
Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513.
Topics: Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Gliosarcoma; Humans; Male; Middle Aged; Time Factors; Topotecan; Treatment Outcome | 2002 |
24 other study(ies) available for topotecan and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Models, Molecular; Molecular Conformation; Quinazolines; Structure-Activity Relationship; Temozolomide; Urea | 2015 |
Controlling the release rate of topotecan from PLGA spheres and increasing its cytotoxicity towards glioblastoma cells by co-loading with calcium chloride.
Topics: Calcium Chloride; Glioblastoma; Humans; Lactic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Topotecan | 2021 |
The effect of iodine-131 beta-particles in combination with A-966492 and Topotecan on radio-sensitization of glioblastoma: An in-vitro study.
Topics: Benzimidazoles; Biomarkers, Tumor; Cell Line, Tumor; Combined Modality Therapy; Glioblastoma; Humans; In Vitro Techniques; Iodine Radioisotopes; Poly(ADP-ribose) Polymerases; Topotecan; Tumor Cells, Cultured | 2021 |
Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming.
Topics: Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase 6; Enzyme Inhibitors; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Sumoylation; Topotecan; Tumor Cells, Cultured | 2017 |
The combination of A-966492 and Topotecan for effective radiosensitization on glioblastoma spheroids.
Topics: Benzimidazoles; Cell Line, Tumor; DNA Topoisomerases, Type I; Glioblastoma; Humans; Radiation Tolerance; Spheroids, Cellular; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan; X-Rays | 2017 |
Detecting hidden batch factors through data-adaptive adjustment for biological effects.
Topics: Algorithms; Gene Expression Profiling; Glioblastoma; Humans; Quality Control; Research Design; Sequence Analysis, RNA; Topotecan | 2018 |
Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Flow Cytometry; Glioblastoma; Humans; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Radiation, Ionizing; Topoisomerase I Inhibitors; Topotecan; Tumor Suppressor Protein p53 | 2014 |
Topotecan enhances immune clearance of gliomas.
Topics: Antibody-Dependent Cell Cytotoxicity; Brain Neoplasms; CD3 Complex; Cell Line, Tumor; Fas Ligand Protein; fas Receptor; Flow Cytometry; Glioblastoma; Humans; Immunotherapy; Interferon-gamma; Signal Transduction; T-Lymphocytes; Topotecan; Up-Regulation | 2009 |
Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Survival; Contrast Media; Convection; Drug Delivery Systems; Gadolinium DTPA; Glioblastoma; Humans; Liposomes; Male; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Survival Rate; Tissue Distribution; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors.
Topics: Animals; Brain Neoplasms; Cell Survival; Disease Models, Animal; Glioblastoma; Immunohistochemistry; Neoplastic Stem Cells; Neuroglia; Platelet-Derived Growth Factor; Rats; Topotecan; Xenograft Model Antitumor Assays | 2011 |
Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.
Topics: Animals; Brain Neoplasms; Drug Delivery Systems; Female; Glioblastoma; Humans; Immunoenzyme Techniques; Liposomes; Luminescent Measurements; Mice; Mice, Nude; Nanotechnology; Survival Rate; Tissue Distribution; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Combined effect of topotecan and irradiation on the survival and the induction of chromosome aberrations in vitro.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line; Cell Survival; Chromosome Aberrations; Colonic Neoplasms; Fibroblasts; Glioblastoma; Humans; Lymphocytes; Metaphase; Neoplasms; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents; Time Factors; Topotecan; Tumor Cells, Cultured | 2002 |
Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Luciferases; Mice; Mice, Nude; Neovascularization, Pathologic; Topoisomerase I Inhibitors; Topotecan; Transcription Factors; Xenograft Model Antitumor Assays | 2004 |
Cell cycle effects of topotecan alone and in combination with irradiation.
Topics: Antineoplastic Agents; Cell Cycle; Cell Cycle Proteins; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Fibroblasts; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Lung; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2005 |
Augmenting tumor sensitivity to topotecan by transient hypoxia.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Carcinoma, Small Cell; Cell Hypoxia; Cell Line, Tumor; Central Nervous System Neoplasms; Glioblastoma; Glucose Transporter Type 1; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Topotecan; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2005 |
American Association for Cancer Research--97th annual meeting.
Topics: Adenine; Animals; Antineoplastic Agents; Benzoquinones; Glioblastoma; HSP90 Heat-Shock Proteins; Humans; Indoles; Janus Kinase 2; Lactams, Macrocyclic; Neoplasms, Experimental; Organophosphonates; Protein Kinase C; Protein Kinase Inhibitors; Signal Transduction; Topotecan; Tyrphostins | 2006 |
Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Glioblastoma; Humans; Male; Polyethylene Glycols; Rats; Rats, Nude; Rats, Sprague-Dawley; Survival Rate; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2007 |
Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.
Topics: Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Densitometry; DNA Damage; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Flow Cytometry; Glioblastoma; Humans; In Situ Nick-End Labeling; Indicators and Reagents; Mutation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinazolines; Signal Transduction; Topotecan; Tumor Suppressor Protein p53 | 2007 |
Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
Topics: Adult; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Craniotomy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Radiation Injuries; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Temozolomide; Topotecan | 2007 |
Construction of optimized bispecific antibodies for selective activation of the death receptor CD95.
Topics: Amino Acid Sequence; Antibodies, Bispecific; Antibody Specificity; Antigens, Neoplasm; Apoptosis; Cell Line, Tumor; Doxorubicin; fas Receptor; Glioblastoma; Humans; Immunoglobulin Fragments; Molecular Sequence Data; Topotecan | 2008 |
Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan.
Topics: Antineoplastic Agents; Camptothecin; Child; Cytoplasm; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Microscopy, Fluorescence; Topotecan; Tumor Cells, Cultured | 1996 |
Interaction of ionizing radiation with topotecan in two human tumor cell lines.
Topics: Antineoplastic Agents; Blotting, Northern; Brain Neoplasms; Camptothecin; Cell Line; Cell Survival; DNA Topoisomerases, Type I; Dose-Response Relationship, Radiation; Gene Expression; Glioblastoma; Humans; Lung Neoplasms; Radiation, Ionizing; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |
Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain Neoplasms; Calcium Channel Blockers; Carmustine; Combined Modality Therapy; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; In Vitro Techniques; Male; Middle Aged; Phenotype; Reverse Transcriptase Polymerase Chain Reaction; Teniposide; Topotecan; Tumor Cells, Cultured; Verapamil; Vincristine | 2000 |
Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Body Weight; Carcinoma, Small Cell; Combined Modality Therapy; Glioblastoma; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Oxygen; Radiation Tolerance; Topotecan; Xenograft Model Antitumor Assays | 2001 |